Zacks Small Cap Has Bearish Estimate for PLX FY2025 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at Zacks Small Cap dropped their FY2025 earnings per share (EPS) estimates for Protalix BioTherapeutics in a research note issued to investors on Tuesday, February 3rd. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.04) for the year, down from their prior estimate of $0.02. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. Zacks Small Cap also issued estimates for Protalix BioTherapeutics’ Q4 2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.06) EPS and FY2027 earnings at $0.08 EPS.

Separately, HC Wainwright dropped their target price on shares of Protalix BioTherapeutics from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 21st. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, Protalix BioTherapeutics presently has a consensus rating of “Buy” and a consensus target price of $12.00.

Protalix BioTherapeutics Stock Up 6.2%

Shares of NYSE PLX opened at $2.90 on Thursday. Protalix BioTherapeutics has a 12-month low of $1.32 and a 12-month high of $3.10. The firm’s 50-day simple moving average is $1.93 and its 200 day simple moving average is $1.91. The company has a market cap of $233.22 million, a price-to-earnings ratio of -22.31 and a beta of -0.25.

Insider Buying and Selling

In other news, CEO Dror Bashan acquired 56,000 shares of the company’s stock in a transaction on Friday, December 19th. The stock was purchased at an average cost of $1.81 per share, with a total value of $101,360.00. Following the acquisition, the chief executive officer owned 188,516 shares of the company’s stock, valued at $341,213.96. This trade represents a 42.26% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC bought a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth $1,223,000. Goldman Sachs Group Inc. lifted its stake in Protalix BioTherapeutics by 482.3% in the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company’s stock valued at $741,000 after buying an additional 239,751 shares during the period. Jane Street Group LLC boosted its holdings in Protalix BioTherapeutics by 159.0% during the first quarter. Jane Street Group LLC now owns 294,318 shares of the company’s stock worth $753,000 after buying an additional 180,702 shares during the last quarter. Evergreen Capital Management LLC acquired a new position in shares of Protalix BioTherapeutics during the 2nd quarter worth about $254,000. Finally, Round Rock Advisors LLC bought a new stake in shares of Protalix BioTherapeutics in the 4th quarter valued at about $279,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.